A Phase I clinical trial of dose-escalated metabolic therapy combined with concomitant radiation therapy in high-grade glioma.

Keren PorperYael ShpatzLuba PlotkinRonit Goldman PechtholdAlisa TalianskiColin E ChampOrit FurmanAriel Shimoni-SebagZvi SymonUri AmitRina HemiHannah KanetyYael MardorZvi R CohenElisheva JanHili GenssinYair AniksterLeor ZachYaacov Richard Lawrence

Published in: Journal of neuro-oncology (2021)

The intervention was well tolerated. Higher serum ketone levels were associated with both dietary intake and metformin use. The recommended phase II dose is eight weeks of a ModAD combined with 850 mg metformin twice daily.

Keyphrases

phase ii
clinical trial
high grade
open label
radiation therapy
randomized controlled trial
phase iii
double blind
low grade
study protocol
physical activity
squamous cell carcinoma
mesenchymal stem cells
bone marrow
preterm birth
replacement therapy
smoking cessation